<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954274</url>
  </required_header>
  <id_info>
    <org_study_id>P170706J</org_study_id>
    <nct_id>NCT04954274</nct_id>
  </id_info>
  <brief_title>Improvement of Live Babies Rates After ICSI, Using cpFT</brief_title>
  <acronym>FERTICSI</acronym>
  <official_title>Improvement of Live Babies Rates After ICSI, Using cpFT: Multicenter Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the improvement of the live births rate after ICSI by supplementing the pre-ICSI&#xD;
      incubation medium of oocytes and that of preimplantation embryos with cpFT at the 1st embryo&#xD;
      transfer for women under 37 years old.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Supplementation of the incubation medium with cFEE should improve the implantation rate and&#xD;
      ART outcome.&#xD;
&#xD;
      As in France ICSI is widely used to achieve good fertilization rates, we decided to use ICSI&#xD;
      to fertilize the egg, and the peptide:&#xD;
&#xD;
        1. to improve chromosome segregation during meiosis, and&#xD;
&#xD;
        2. to improve in vitro embryogenesis after ICSI. Hence the protocol includes an oocyte&#xD;
           preincubation step prior to ICSI and a co incubation of the embryo with the molecule&#xD;
           during blastocyst formation.&#xD;
&#xD;
      Hence our protocol includes:&#xD;
&#xD;
        1. - a preincubation of the decoronized oocytes with the peptide prior to ICSI, and&#xD;
&#xD;
        2. - a coincubation of the developing embryo with the molecule.&#xD;
&#xD;
      The principal criteria will be the live baby rate after the first embryo transfer (using the&#xD;
      best embryo). As the oocyte loses its strength as the women is getting older, the main&#xD;
      criteria will be evaluated for women under 37 years old.&#xD;
&#xD;
      Randomization: every couple will be randomly assigned to the Control or the Treated group.&#xD;
&#xD;
      Treated group: After egg retrieval, the oocyte will be decoronized and incubated prior to&#xD;
      ICSI procedure into CSCM-C (Irvine) medium supplemented with the molecule.&#xD;
&#xD;
      Control group: similar protocol of incubation but without the molecule. After ICSI the zygote&#xD;
      will be incubated until the blastocyste stage in CSCM-C medium (Irvine).&#xD;
&#xD;
      Embryo transfer will be limited to only one blastocyst, fresh or delayed after&#xD;
      cryopreservation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 26, 2021</start_date>
  <completion_date type="Anticipated">August 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 26, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>there will be two groups: one treated by supplementation of the culture medium with 1 Micromolar of the molecule, the other being the control group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate after the first embryo transfer</measure>
    <time_frame>28 months after the first inclusion</time_frame>
    <description>Demonstration of the improvement in the rate of live births after ICSI by supplementing the pre-ICSI incubation medium of oocytes and that of preimplantation embryos with cpFT (1µM) during the 1st embryo transfer in women under 37 years of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Metaphase II oocytes</measure>
    <time_frame>Through study completion average 16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of the embryonic culture</measure>
    <time_frame>16 months after the first inclusion</time_frame>
    <description>The measure evaluates the rate and number of fertilized eggs over the total number of metaphase 2 oocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the kinetics of embryonic development when possible.</measure>
    <time_frame>16 months after the first inclusion</time_frame>
    <description>The embryos will be kept in an incubator with an embryoscope so that their cleavage sequences will be registered &quot;when possible&quot;. The criteria will analysis the cleavage sequences of all embryos during preimplantation embryogenesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryonic quality at the blastocyst stage</measure>
    <time_frame>Day 5-6 after ICSI</time_frame>
    <description>All the embryos that will reach the blastocyst stage will be evaluated according to the Gardner criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of the embryos after vitrification</measure>
    <time_frame>Day 5-6 after ICSI</time_frame>
    <description>The percentage of Good and Top embryos after thawing will be compared to the grading for the same embryo before cryopreservation according to Gardner criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate with positive Beta hCG after transfer</measure>
    <time_frame>20 months after the first inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rates with cardiac activity</measure>
    <time_frame>22 months after the first inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of miscarriages per pregnancy</measure>
    <time_frame>22 months after the first inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of abnormality on morphological ultrasounds</measure>
    <time_frame>28 months after the beginning of the study</time_frame>
    <description>It reports the percentage of morphological ultrasounds showing an abnormality in the fetus morphology on the total number of morphological ultrasounds performed for all the pregnancies depending of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of neonatal abnormality</measure>
    <time_frame>28 months after the beginning of the study</time_frame>
    <description>It reports the percentage of neonatal baby examination showing an abnormality over the total number of neonatal baby examination performed for all the babies who will born during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>children's development</measure>
    <time_frame>45 months after the beginning of the study</time_frame>
    <description>It reports the percentage of one year old baby examinations showing an abnormality over the total number of one year old baby examinations performed for all the babies who will born during the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Infertility</condition>
  <condition>Oocyte</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Fertiline group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated by supplementation of the culture medium with the molecule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No supplementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclic peptide Fertiline</intervention_name>
    <description>Upon retrieval, the oocyte will be decoronized and incubated prior to ICSI procedure into CSCC-M medium supplemented with the molecule.&#xD;
After ICSI, the zygote will be incubated in CSCM-C medium supplemented with the peptide.</description>
    <arm_group_label>Fertiline group</arm_group_label>
    <other_name>cFEE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Couples eligible for a first attempt at Assisted Reproduction (AMP).&#xD;
&#xD;
          -  Couples asking for Assisted Reproductive Technology, and requiring an ICS procedure.&#xD;
&#xD;
          -  Women aged 18 to 36 inclusive.&#xD;
&#xD;
          -  Men aged 18 to 58 inclusive&#xD;
&#xD;
          -  Use of CSCM-C culture medium from Biocare / Irvine, exclusively.&#xD;
&#xD;
          -  People affiliated to a Social Security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of consent&#xD;
&#xD;
          -  Early menopause.&#xD;
&#xD;
          -  Couples under IVF or Intra Uterine Insemination treatment.&#xD;
&#xD;
          -  Patients resumed after a first attempt by the couple.&#xD;
&#xD;
          -  People unable to follow protocol visits in France.&#xD;
&#xD;
          -  Couple with a contraindication to treatment with ART.&#xD;
&#xD;
          -  Women with a contraindication to treatment with ART or an associated pathology such&#xD;
             as: hypertension, risk of eclampsia, viral risk, family genetic problems, diabetes,&#xD;
             uterine partitions, synechiae adhesions, adenomyosis or any other contraindication&#xD;
             judged as such by the investigator.&#xD;
&#xD;
          -  AMP with donation of gametes or embryos.&#xD;
&#xD;
          -  Frozen sperm.&#xD;
&#xD;
          -  Participant under guardianship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Philippe Mr WOLF, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, Hospital Cochin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Philippe Mr WOLF, MD-PhD</last_name>
    <phone>01 58 41 37 31</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-philippe.wolf@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine PATRAT, MD-PhD</last_name>
    <phone>01 58 41 37 34</phone>
    <phone_ext>+33</phone_ext>
    <email>catherine.patrat@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department Biology of Reproduction, Hospital Cochin AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean Philippe Mr WOLF, MD-PhD</last_name>
      <phone>33 1 58 41 37 31</phone>
      <phone_ext>0033</phone_ext>
      <email>jean-philippe.wolf@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Barraud-Lange V, Naud-Barriant N, Ducot B, Chambris S, Bomsel M, Wolf JP, Ziyyat A. Cyclic QDE peptide increases fertilization rates and provides healthy pups in mouse. Fertil Steril. 2009 May;91(5 Suppl):2110-5. doi: 10.1016/j.fertnstert.2008.05.088. Epub 2008 Aug 9.</citation>
    <PMID>18692807</PMID>
  </reference>
  <reference>
    <citation>Ziyyat A, Naud-Barriant N, Barraud-Lange V, Chevalier F, Kulski O, Lemkecher T, Bomsel M, Wolf JP. Cyclic FEE peptide increases human gamete fusion and potentiates its RGD-induced inhibition. Hum Reprod. 2005 Dec;20(12):3452-8. Epub 2005 Aug 11.</citation>
    <PMID>16096325</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>Femal infertility</keyword>
  <keyword>Assisted Reproduction Technology outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

